ClinicalTrials.gg
RecruitingNCT07848191Updated Nov 16, 2026

Rezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 Fibrosis

A Phase 4 interventional study of Rezdiffra and Resmetirom in MASH - Metabolic Dysfunction-Associated Steatohepatitis, sponsored by Madrigal Pharmaceuticals, Inc.. Recruiting at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Madrigal Pharmaceuticals, Inc. · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 16, 2026Now RecruitingFirst site in United States+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing pioglitazone in Fatty Liver — 2 open to participants now, 2 under way, none of them phase 3. Pioglitazone · Fatty Liver.

Planned enrollment
2nd of 11
150 · median 51
Started
2026
the only one that year
Phase 4
5 of 11
2 open now
Registered
11th of 11
by date
Lead sponsor
1 of 11
Madrigal Pharmaceuticals, Inc.

Among the 11 studies testing pioglitazone in Fatty Liver, this one is the 2nd largest by planned enrollment, is the only one that started in 2026, is one of 5 in phase 4, and was the 11th registered.

Fatty Liver

663 studies on the registry are indexed under Fatty Liver; 185 are open to participants now.

Browse Fatty Liver studies →

Open to participants now

2 of the 11 studies testing pioglitazone in Fatty Liver are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About pioglitazone

Pioglitazone: first FDA approval 1999 (ACTOS), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 117 Fatty Liver studies recruiting now, 35 (30%) set no upper age limit and 63 (54%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing pioglitazone in Fatty Liver, or all of them as a file.
02

Study summary

To determine the safety of Rezdiffra (Resmetirom) when administered alongside common prescriptions for Diabetes Metellus (Farxiga/dapagliflozin \& Actos/pioglitazone)

Read the detailed description

This Phase 4 study will evaluate the safety and tolerability of REZDIFFRA® (resmetirom) when used in combination with concomitant therapies commonly used to treat diabetes in adults with metabolic dysfunction-associated steatohepatitis (MASH) and noncirrhotic, moderate-to-advanced (F2-F3) fibrosis. The concomitant therapies evaluated in this study will include ACTOS®/pioglitazone and FARXIGA®/dapagliflozin. All study medications will be administered according to their approved labeling.

Participants will be assigned to one of six cohorts based on their existing therapy and the concomitant medication being evaluated. In Group A, participants who are receiving a stable dose of pioglitazone or dapagliflozin will initiate resmetirom. In Group B, participants who are receiving a stable dose of REZDIFFRA will initiate pioglitazone or dapagliflozin. In Group C, participants who are not currently receiving either treatment will initiate resmetirom and either pioglitazone or dapagliflozin in a staggered manner, with a 4- to 6-week run-in period between initiation of the first and second medications.

Approximately 25 participants are planned for each of the six cohorts, for a maximum planned enrollment of approximately 150 participants. Following initiation of combination treatment, participants will be followed for 24 weeks, with a safety follow-up visit approximately 4 weeks after completion of treatment.

Safety and tolerability will be characterized through assessment of treatment-emergent adverse events, physical examinations, vital signs, clinical laboratory parameters, treatment discontinuations, and dose interruptions or reductions. Exploratory assessments will evaluate changes in liver fat by MRI-PDFF, noninvasive measures of hepatic steatosis and fibrosis, and biomarkers related to MASH disease state, insulin resistance, glucose homeostasis, body weight, and liver function.

03

Conditions studied

  • MASH - Metabolic Dysfunction-Associated Steatohepatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All Subjects:

  1. Willing to participate in the study and provide written .
  2. Meets all requirements per REZDIFFRA Prescribing Information, in the opinion of the PI.
  3. Male and female adults ≥18 of age at time of screening.
  4. Evidence of hepatic steatosis consistent with MASH demonstrated by an MRI-PDFF fat fraction >5% obtained during second screening period.
  5. Evidence of moderate-to-advanced fibrosis (F2-F3) without cirrhosis.
  6. Stable medical conditions and background medications (non-concomitant medications as defined in this protocol) per PI judgement.
  7. Female subjects of are eligible if they have a negative serum pregnancy test (beta human chorionic gonadotropin), are not breastfeeding, and do not plan to become pregnant during the study and agree to use 1 highly effective method during the study and for at least 30 days after newly introduced medication administration.

    Highly effective birth control methods include hormonal and non-hormonal intrauterine device, combination estrogen-progesterone hormonal contraception (oral, transdermal, or vaginal), tubal ligation, a vasectomized or sterile male partner, or sexual abstinence (defined as refraining from heterosexual intercourse), from Screening throughout the study, and for at least 30 days after newly introduced medication administration. Reliance on abstinence from heterosexual intercourse is acceptable only if it is the subject's habitual practice. NOTE: Female subjects who are not of (ie, surgically [bilateral oophorectomy, hysterectomy] or naturally sterile [>12 consecutive months without menses]) do not require contraception during the study.

  8. Must be taking a stable dose of ACTOS/pioglitazone for at least 2 months prior to Baseline. (Group A1)
  9. Must be taking a stable dose of FARXIGA/dapagliflozin for at least 2 months prior to Baseline. (Group A2)
  10. Must be taking a stable dose of REZDIFFRA for at least 2 months prior to Baseline. (Groups B1 and B2)
  11. Must not have previously taken RESMETIROM or ACTOS/pioglitazone or FARXIGA/dapagliflozin. (Group C)
  12. For Groups A1, B1, and C1: Meets all requirements per ACTOS/pioglitazone Prescribing Information, in the opinion of the PI.
  13. For Groups B1 and C1: (ie, naïve to ACTOS/pioglitazone): at screening ≥7.0% and ≤10.0%.
  14. For Groups A2, B2, and C2: Meets all requirements per FARXIGA/dapagliflozin Prescribing Information, in the opinion of the PI.
  15. For Groups B2 and C2 (ie, naïve to FARXIGA/dapagliflozin): HbA1c at screening ≥7.0% and ≤10.0%.

Exclusion criteria

Exclusion Criteria All subjects

  1. Off label use of the commercially available study medications.
  2. Evidence of cirrhosis demonstrated by clinical, imaging, histologic, or NIT thresholds consistent with cirrhosis.
  3. Other chronic liver diseases (eg, viral hepatitis, hepatitis, hemochromatosis).
  4. Documented history of decompensated liver disease.
  5. Use of rosuvastatin or simvastatin at a dose greater than 20 mg/day, or pravastatin or atorvastatin at a dose greater than 40 mg/day, at the time of the first dose of resmetirom. Subjects receiving a statin dose above the applicable limit during the screening period may remain eligible if the dose is reduced to the applicable maximum permitted dose before the first dose of resmetirom.
  6. Any other condition which, in the opinion of the investigator, would impede compliance, hinder completion of the study, compromise the well-being of the subject, or interfere with the study outcomes.
  7. Active or suspected bladder cancer.
  8. Diagnosis of heart failure.
  9. \< 60mL/min/1.73 m2
  10. Developmental/intellectual disability, limited capacity of recognition, any history of emotional and/or psychiatric illness, inability to follow the study procedures, or any other condition which, in the opinion of the Investigator, would impede compliance, hinder completion of the study, compromise the well-being of the patient, or interfere with the study outcomes.
  11. Individuals who are currently incarcerated or who are anticipated to be incarcerated during the study period.

    Groups B and C:

  12. Unable to secure a prescription for a concomitant medication.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Other
    Actos (pioglitazone) [Ongoing] | Resmetirom [New]

    Experienced Actos/Pioglitazone + Resmetirom Naive (A1)

    Drug: Resmetirom · Drug: ACTOS/pioglitazone

  • Other
    Farxiga (dapagliflozin) [Ongoing] | Resmetirom [New]

    Experienced Farxiga/Dapagliflozin + Resmetirom Naive (A2)

    Drug: Resmetirom · Drug: FARXIGA/dapagliflozin

  • Other
    REZDIFFRA [Ongoing] | Actos (pioglitazone) [New]

    Experienced REZDIFFRA + Actos/Pioglitazone Naive (B1)

    Drug: Rezdiffra · Drug: ACTOS/pioglitazone

  • Other
    REZDIFFRA [Ongoing] | Farxiga (dapagliflozin) [New]

    Experienced REZDIFFRA + Farxiga/Dapagliflozin Naive (B2)

    Drug: Rezdiffra · Drug: FARXIGA/dapagliflozin

  • Other
    Actos (pioglitazone) [New] | Resmetirom [New]

    Naive Actos/Pioglitazone + Resmetirom Naive (C2)

    Drug: Resmetirom · Drug: ACTOS/pioglitazone

  • Other
    Farxiga (dapagliflozin) [New] | Resmetirom [New]

    Naïve Farxiga/dapagliflozin + Resmetirom Naïve (C2)

    Drug: Resmetirom · Drug: FARXIGA/dapagliflozin

Interventions

  • All study medications will be administered according to their labels: • REZDIFFRA- Label weight-based dosing: * \<100 kg: 80 mg orally once daily. * ≥100 kg: 100 mg orally once daily

  • Resmetirom - weight-based dosing: * \<100 kg: 80 mg orally once daily. * ≥100 kg: 100 mg orally once daily

  • DrugACTOS/pioglitazone

    Drug page: Pioglitazone

    Label dosing recommendations indicated for patients without congestive heart failure (15 or 30 mg orally once daily; if tolerated, increase by 15 mg increments up to a maximum of 45 mg orally once daily for additional glycemic control

  • DrugFARXIGA/dapagliflozin

    Drug page: Dapagliflozin

    Label dosing recommendations indicated for glycemic control in type 2 diabetes (5 mg orally once daily; if tolerated, increase to 10 mg orally once daily for additional glycemic control)

06

What researchers measure

Primary outcomes

  1. Number and Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

    The total number of TEAEs and the number and percentage of participants with at least 1 TEAE will be summarized by study group. TEAEs will also be summarized by System Organ Class and Preferred Term.

    Time frame: From First Dose of newly introduced medication up to 28 weeks

  2. Number and Percentage of Participants With TEAEs by Maximum Severity

    The number and percentage of participants with TEAEs will be summarized by maximum severity using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0.

    Time frame: From First Dose of newly introduced medication up to 28 weeks

  3. Number and Percentage of Participants With TEAEs by Relationship to Study Medication

    The number and percentage of participants with TEAEs assessed as Related or Not Related to each applicable study medication (REZDIFFRA/resmetirom, ACTOS/pioglitazone, or FARXIGA/dapagliflozin) will be summarized by study group.

    Time frame: From First Dose of newly introduced medication up to 28 weeks

07

Study locations

11 of 16 sites recruiting
  • Arizona Liver Health - Chandler
    Chandler, Arizona 85224, United States
    Recruiting
  • Arkansas Gastroenterology
    North Little Rock, Arkansas 72117, United States
    Recruiting
  • Southern California Research Center
    Coronado, California 92118, United States
    Not yet recruiting
  • Inland Empire Liver Foundation
    Rialto, California 37411, United States
    Recruiting
  • Florida Research Institute
    Lakewood Rch, Florida 34211, United States
    Recruiting
  • Gastro Health PLLC Galloway
    Miami, Florida 33176, United States
    Recruiting
  • Med Research of Florida, LLC
    Miami, Florida 33186, United States
    Not yet recruiting
  • Elevate Clinical Research
    Lake Charles, Louisiana 70605, United States
    Recruiting
  • Centricity Research - Morehead City - Multispecialty - PPDS
    Morehead City, North Carolina 28557, United States
    Recruiting
  • Gastro Health Research
    Cincinnati, Ohio 45219, United States
    Recruiting
  • University Diabetes and Endocrine Consultants
    Chattanooga, Tennessee 37411, United States
    Not yet recruiting
  • Texas Clinical Research Institute
    Arlington, Texas 76012-3216, United States
    Recruiting
  • South Texas Endocrinology & Metabolism Center
    Corpus Christi, Texas 78414, United States
    Recruiting
  • The Liver Institute at Methodist Dallas Medical Center
    Dallas, Texas 75234, United States
    Recruiting
  • Elevate Clinical Research - McAllen - PPDS
    McAllen, Texas 78504, United States
    Not yet recruiting
  • Diabetes and Glandular Disease Clinic, PA
    San Antonio, Texas 78229, United States
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2026 (actual). Primary completion is estimated for Nov 2027, 13 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Oct 2026, on Oct 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2026
First posted
Sep 29, 2026
StartActual
Oct 7, 2026was Sep 2026
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 16, 2026
Sites
16 sites added — first site in United States. 8 sites changed recruiting status (8 now recruiting)
Show 8 sites
  • Arizona Liver Health - Chandler · Chandler, United StatesNot yet recruiting→Recruiting
  • Arkansas Gastroenterology · North Little Rock, United StatesNot yet recruiting→Recruiting
  • Inland Empire Liver Foundation · Rialto, United StatesNot yet recruiting→Recruiting
  • Florida Research Institute · Lakewood Rch, United StatesNot yet recruiting→Recruiting
  • Centricity Research - Morehead City - Multispecialty - PPDS · Morehead City, United StatesNot yet recruiting→Recruiting
  • Texas Clinical Research Institute · Arlington, United StatesNot yet recruiting→Recruiting
  • South Texas Endocrinology & Metabolism Center · Corpus Christi, United StatesNot yet recruiting→Recruiting
  • The Liver Institute at Methodist Dallas Medical Center · Dallas, United StatesNot yet recruiting→Recruiting
Show 16 added (16 United States)
  • Arizona Liver Health - Chandler · Chandler, United States
  • Arkansas Gastroenterology · North Little Rock, United States
  • Southern California Research Center · Coronado, United States
  • Inland Empire Liver Foundation · Rialto, United States
  • Florida Research Institute · Lakewood Rch, United States
  • Gastro Health PLLC Galloway · Miami, United States
  • Med Research of Florida, LLC · Miami, United States
  • Elevate Clinical Research · Lake Charles, United States
  • Centricity Research - Morehead City - Multispecialty - PPDS · Morehead City, United States
  • Gastro Health Research · Cincinnati, United States
  • University Diabetes and Endocrine Consultants · Chattanooga, United States
  • Texas Clinical Research Institute · Arlington, United States
  • South Texas Endocrinology & Metabolism Center · Corpus Christi, United States
  • The Liver Institute at Methodist Dallas Medical Center · Dallas, United States
  • Elevate Clinical Research - McAllen - PPDS · McAllen, United States
  • Diabetes and Glandular Disease Clinic, PA · San Antonio, United States
across 2 updates, Oct 16, 2026 – Nov 16, 2026
Start date
Sep 2026→Oct 7, 2026 (actual)
Oct 16, 2026
Registered
First appeared on the registry
Sep 29, 2026
Show all 3 updates
  1. Nov 16, 2026
    8 sites changed recruiting status (8 now recruiting)
    Show 8 sites
    • Arizona Liver Health - Chandler · Chandler, United StatesNot yet recruiting→Recruiting
    • Arkansas Gastroenterology · North Little Rock, United StatesNot yet recruiting→Recruiting
    • Inland Empire Liver Foundation · Rialto, United StatesNot yet recruiting→Recruiting
    • Florida Research Institute · Lakewood Rch, United StatesNot yet recruiting→Recruiting
    • Centricity Research - Morehead City - Multispecialty - PPDS · Morehead City, United StatesNot yet recruiting→Recruiting
    • Texas Clinical Research Institute · Arlington, United StatesNot yet recruiting→Recruiting
    • South Texas Endocrinology & Metabolism Center · Corpus Christi, United StatesNot yet recruiting→Recruiting
    • The Liver Institute at Methodist Dallas Medical Center · Dallas, United StatesNot yet recruiting→Recruiting
    + 1 other change: verification date
  2. Oct 16, 2026
    Not yet recruiting→Recruiting
    16 sites added — first site in United States
    Show 16 added (16 United States)
    • Arizona Liver Health - Chandler · Chandler, United States
    • Arkansas Gastroenterology · North Little Rock, United States
    • Southern California Research Center · Coronado, United States
    • Inland Empire Liver Foundation · Rialto, United States
    • Florida Research Institute · Lakewood Rch, United States
    • Gastro Health PLLC Galloway · Miami, United States
    • Med Research of Florida, LLC · Miami, United States
    • Elevate Clinical Research · Lake Charles, United States
    • Centricity Research - Morehead City - Multispecialty - PPDS · Morehead City, United States
    • Gastro Health Research · Cincinnati, United States
    • University Diabetes and Endocrine Consultants · Chattanooga, United States
    • Texas Clinical Research Institute · Arlington, United States
    • South Texas Endocrinology & Metabolism Center · Corpus Christi, United States
    • The Liver Institute at Methodist Dallas Medical Center · Dallas, United States
    • Elevate Clinical Research - McAllen - PPDS · McAllen, United States
    • Diabetes and Glandular Disease Clinic, PA · San Antonio, United States
    Start date Sep 2026→Oct 7, 2026 (now actual)
    + 1 other change: verification date
  3. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07848191
Responsible party
Sponsor
First posted
Sep 29, 2026
Start date
Oct 7, 2026
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Tom Hare
Contact
info@madrigalpharma.com
267-406-0611
Tom Hare
study director · Madrigal Pharmaceuticals, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Resmetirom · Pioglitazone · Dapagliflozin

Start the discussion